Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 4.43%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Company Guidance
During the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call, guidance was provided on several key metrics and future plans for the company. The company highlighted an initial data set from the CRDF-004 trial, which showed a 64% overall response rate (ORR) for patients on the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial focuses on first-line RAS-mutated metastatic colorectal cancer (mCRC), and aims to complete enrollment of 90 evaluable patients in early 2025. The company plans to release additional clinical data in the first half of 2025. Financially, Cardiff Oncology reported $91.7 million in cash and short-term investments as of December 31, 2024, following a $40 million capital raise. The company projects that these resources will support operations into the first quarter of 2027, with a quarterly cash burn of $10.3 million in Q4 2024. Additionally, Cardiff Oncology strengthened its intellectual property portfolio with a new patent for onvansertib, expected to expire no earlier than 2043.Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Successful Capital Raise
Cardiff Oncology successfully completed a $40 million capital raise, enhancing financial stability and resources for future developments.
Advancement in Intellectual Property
A new patent was issued covering the use of onvansertib with bevacizumab for KRAS-mutated mCRC, extending intellectual property protection until at least 2043.
Strong Financial Position
Cash and short-term investments totaled $91.7 million, providing a financial runway into Q1 2027.
Positive Preclinical Results in Breast Cancer
Onvansertib showed promising results in preclinical studies, demonstrating synergistic activity with paclitaxel and ENHERTU in drug-resistant HR-positive breast cancer models.
---
CRDF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRDF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $4.06 | $4.24 | +4.43% |
| Nov 07, 2024 | $4.09 | $3.08 | -24.69% |
| Aug 08, 2024 | $2.13 | $2.38 | +11.74% |
| May 02, 2024 | $4.48 | $3.52 | -21.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cardiff Oncology, Inc. (CRDF) report earnings?
Cardiff Oncology, Inc. (CRDF) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Cardiff Oncology, Inc. (CRDF) earnings time?
Cardiff Oncology, Inc. (CRDF) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRDF EPS forecast?
CRDF EPS forecast for the fiscal quarter 2025 (Q1) is -0.19.
---